Key facts

  • A world lead within diabetes and haemostasis management
  • Sales totalled DKK 60.8 billion in 2010 (Eur 8.2 billion)
  • In 2010 total insulin market of 51% and modern insulin market share 46%, measured by volume (Source IMS)
  • Some 30.014 Full time employees
  • Focus on core areas with large unmet medical needs: Diabetes care, haemostasis, growth hormone disorders and other biopharmaceuticals
  • Strong global marketing network
  • Listed on NASDAQ OMX Copenhagen and New York Exchanges